Price: £190 + phlebotomy fee

The Nutrition and Lifestyle DNA test will screen 40 genes to reveal how your body responds to the foods you eat and how your genes can affect your weight, physical activity, injury risk, mental health, and sleep. It will also reveal if you are at higher risk of certain nutritional diseases, empowering you with the knowledge to personalise your nutrition and exercise based on your DNA.

Price: £105 + phlebotomy fee

Lactose intolerance is a common digestive problem. Symptoms can include flatulence, diarrhoea, bloating, stomach pains and nausea within a few hours of consuming food containing lactose.

There are 4 types of lactose intolerance with primary lactose intolerance being the most common. This type is inherited and caused by a genetic fault.

Price: £105 + phlebotomy fee

Around 1 in 100 people in the UK are Coeliac, with an estimated 70% of people undiagnosed. A Coeliac Disease test includes genetic testing to identify if you carry the HLA-DQ risk marker.

.

Price: £80 + phlebotomy fee

Genetic Haemochromatosis is the UK's most commonly inherited condition causing your body to absorb too much iron, which in turn can lead to heart disease, liver disease, diabetes, and cancer.

Over 9 million people in the UK are estimated to have a genetic predisposition to haemochromatosis or iron overload disorder.

Price: £585 + phlebotomy fee

FH is passed down through families and is caused by one or more faulty genes. The faulty gene mutations means your liver is unable to remove excess 'bad' cholesterol (LDL cholesterol).

Individuals with FH are at greater risk of heart disease if the condition is left untreated with many individuals unaware they have it.

Price: £870 + phlebotomy fee

Up to 1 in 100 people can have some form of inherited cardiac condition. Our Inherited Cardiac Conditions genetic test covers 174 different genes related to 17 inherited cardiac conditions including cardiomyopathies, arrhythmias, arteriopathies and lipid disorders.

Price: £560

Around 5-10% of breast cancer cases are thought to be hereditary and up to 20% of ovarian cancers are genetic. A BRCA gene test like our hereditary breast and ovarian cancer genetic risk test covers 8 different genes including BRCA1 and BRCA2 associated with increased risk of hereditary breast and ovarian cancer.

Price: £560

It is estimated that 1 in 15 males and 1 in 8 females will develop bowel cancer in their lifetime with around 5-10% of all bowel cancers thought to be caused by a mutation in a known gene. The bowel cancer risk test screens for mutations in 11 different genes associated with increased risk of bowel cancer.

Price: £560

It is estimated that around 1 in 8 men will be diagnosed with prostate cancer in their lifetime with around 10% of prostate cancers thought to be inherited. The prostate cancer risk test measures for mutations in 14 different genes associated with increased risk of prostate cancer.

Price: £850

Up to 1 in 10 cancers are caused by hereditary gene mutations. The Inherited cancer genetic test covers 94 different genes suspected to play a role in predisposing cancer, including genes associated with increased risk of breast, ovarian, prostate, colorectal and thyroid cancer.

Price: £1200

TruCheck™ Early Cancer Screening blood test is a thorough check for the existence of cancer in your body, identifying which type of cancer(s) you have, and from which organ they have originated.

Trucheck covers screening for over 70 solid organ cancers, including:

Melanoma, Head and Nick, Salivary Gland, Thyroid, Lung, Breast, Liver, Biliary Tract, Gastro-Intestinal, Soft Tissue and Osteosarcomas, Mesothelioma, Urinary Tract, Gynaecological, Male Cancers including Prostate, CNS, Thymus, Adrenal, Skin.

Price: £420

Stockholm3 is a blood test designed for the early detection of prostate cancer. It assesses five protein markers and multiple genetic markers. The result is a risk score that estimates the likelihood of prostate cancer spreading. If the risk is elevated, a referral to a urologist for further evaluation is advised. For low or normal risk, retesting is recommended within two to six years.

Early detection is crucial for successfully identifying prostate cancer. Stockholm3 identifies high-risk individuals even when PSA levels appear normal.

Compared to PSA testing in routine clinical practice, Stockholm3 detects twice as many men with aggressive prostate cancer requiring treatment.